Expressions of SATB1 and Bcl-2 in invasive breast cancer and their clinical significance

doi:10.3877/cma.j.issn.1674-0807.2010.05.009

Abstract

Abstract:

Objective

To study the expressions of SATB1 (special AT-rich sequence-binding protein-1)and Bcl-2 (B cell lymphoma/leukemia-2)in invasive breast cancer,their relationship with clinical pathological parameters and their clinical significance.

Methods

The expressions of SATB1,Bcl-2,estrogen receptor(ER)and progesterone receptor(PR)were studied in 84 invasive breast cancer samples using SP immunohistochemistry(IHC)and the relationship of SATB1 and Bcl-2 with clinical pathological parameters and prognosis was analyzed.Chi square test,Mann-Whitney U test and Kruskal-Wallis H test were used for qualitative data.Spearman test was used to analyze the correlation between groups.Kaplan-Meier method,Logrank test and COX model analysis were used for survival analysis.

Result

The expression of SATB1 in breast cancer was significantly higher than that in adjacent normal tissue(χ²=30.03,P=0.00).The expression of Bcl-2 in breast cancer was significant1y lower than that in adjacent normal tissue(χ²=5.01,P=0.03).The expression of SATB1 was not related with the age,tumor size and histo1ogical type(P＞0.05),but increased with the increase of the histological grade,clinical stage and lymph node metastasis(P ＜0.05).The expression of Bcl-2 was related with histological grade and lymph node metastasis(P＜0.05),but descended with increase of histological grade and lymph node metastasis.The expression of SATB1 was correlated with ER(r=-0.31,P=0.01)and PR(r=-0.29,P=0.01),but was not correlated with Bcl-2(r=-0.21,P=0.05).Bcl-2 was not correlated with ER(r=0.09,P=0.40)and PR(r=0.17,P=0.12).SATB1 was statistically correlated with the prognosis(χ²=32.55,P=0.00).SATB1,histological grade,lymph node metastasis and ER were independent prognostic factors of invasive breast cancer(P＜0.05).

Conclusion

SATB1 may be related to malignant process of breast cancer.Overexpression of SATB1 indicates poor prognosis in breast cancer patients.SATB1 may become a new independent prognostic factor for breast cancer.High-expression of Bcl-2 indicates good biological behaviour of breast cancer.

Key words: Breast neoplasms, Special AT-rich sequence-binding protein, B cell lymphoma/leukemia-2, Estrogen receptor, Progesterone receptor, Prognosis

Jian-liang ZHUANG, Yong-wei TIAN, Rong-yu XU, Zi-jian SU. Expressions of SATB1 and Bcl-2 in invasive breast cancer and their clinical significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2010, 04(05): 566-580.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2010.05.009

https://zhrxbzz.cma-cmc.com.cn/EN/Y2010/V04/I05/566

Figures/Tables 22

References 19

[1]	Han HY,Russo J,Kohwi Y,et a1.SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis.Nature,2008,452:187-193.
[2]	李明全细云.乳腺癌组织学分级与ER、PR、CerbB-2、Ki-67表达的关系.中国现代医药杂志,2009,11:15-17.
[3]	许东哲,金哲洙,李瑞永.乳腺癌中Bcl-2和Ki-67表达及其临床病理意义.中华中西医杂志,2009,10:241-244.
[4]	Cai S,Lee CC,Kohwi Shigematsu T.SATB1 packages densely looped,transcriptionally active chromatin for coordinated expression of cytokine genes.Nat Genet,2006,38:1278-1288.
[5]	Pavan Kumar P,Purbey PK,Sinha CK,et al.Phosphorylation of SATB1,a global gene regulator,acts as a molecular switch regulating its transcriptional activity in vivo.Mol Cell,2006,22:231-243.
[6]	Purbey PK,Singh S,Kumar PP,et a1.PDZ domain-mediated dimerization and homeodomain-directed specificity are required for high-affinity DNA binding by SATB1.Nucleic Acids Res,2008,36:2107-2122.
[7]	Mai JC,Ellenbogen RG.SATB1:the convergence of carcinogenesis and chromatin conformation.Neurosurgery,2008,63:6.
[8]	Russo J,Han HJ,Kohwi Y,et al.New advances in breast cancer metastasis.Womens Health(Lond Engl),2008,4:547-549.
[9]	Alvarez JD,Yasui DH,Niida H.The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development.Genes Dev,2000,14:521-535.
[10]	周来勇,刘芳,童健,等.实时荧光定量RT-PCR 分析非小细胞肺癌SATB1的表达和临床病理意义.南方医科大学学报,2009,29:534-537.
[11]	Cai S,Han HJ,Kohwi Shigematsu T.Tissue-specific nuclear architecture and gene expression regulated by SATB1.Nat Genet,2003,34:42-51.
[12]	马斌林,孙刚.ER、PR 和PS2在乳腺浸润性导管癌中的表达及其临床意义.中华乳腺病杂志:电子版,2008,2:48-54.
[13]	Ignatiadis M,Georgoulias V,Mavroudis D.Circulating tumor cells in breast cancer.Curr Opin Obstet Gynecol,2008,20:55-60.
[14]	Zinkel S,Gross A,Yang E.BCL2 family in DNA damage and cell cycle control.Cell Death Differ,2006,13:1351-1359.
[15]	Nadler Y,Camp RL,Giltnane JM,et a1.Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.Breast Cancer Res,2008,10:35.
[16]	Chang BS,Minn AJ,Muchmore SW,et al.Identification of a novel regulatory domain in Bcl-X(L)and Bcl-2.EMBO J,1997,16:968-977.
[17]	Pezzella F,Gatter K,What is the value of bcl-2 protein detecton for histopathologists? Histopathology,1995,26:89-93.
[18]	TreréD,Montanaro L,Ceccarelli C,et a1.Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast.Ann Oncol,2007,18:1004-1014.
[19]	Martinez Arribas F,Alvarez T,Del Val G,et a1.Bcl-2 expression in breast cancer:a comparative study at the mRNA and protein level.Anticancer Res,2007,27:219-222.

组别	例数	SATB1				Bcl-2
组别	例数	阳性	百分率(%)	χ²值	P值	阳性	百分率(%)	χ²值	P值
浸润性乳腺癌	84	57	67.9	30.03	0.00	54	64.5	5.01	0.03
乳腺癌旁组织	20	0	0			18	90.0

组别	例数	SATB1				Bcl-2
组别	例数	阳性	百分率(%)	χ²值	P值	阳性	百分率(%)	χ²值	P值
浸润性乳腺癌	84	57	67.9	30.03	0.00	54	64.5	5.01	0.03
乳腺癌旁组织	20	0	0			18	90.0

病理因素	例数	Bcl-2				统计量	P值
病理因素	例数	-	+	++	+++	统计量	P值
年龄						-1.16	0.25
＜50岁	50	21	9	11	9
≥50岁	34	9	9	8	8
肿瘤直径						-0.55	0.59
＜3 cm	38	16	7	6	9
≥3 cm	46	14	11	13	8
组织学分型						-0.21	0.84
浸润性导管癌	61	23	12	13	13
浸润性小叶癌	23	7	6	6	4
组织学分级						11.47	0.00
Ⅰ级	30	5	8	6	11
Ⅱ级	30	11	6	8	5
Ⅲ级	24	14	4	5	1
临床分期						-0.54	0.59
Ⅰ+Ⅱ期	56	22	11	11	12
Ⅲ期	28	8	7	8	5
淋巴结转移						-2.02	0.04
无	31	8	6	7	10
有	53	22	12	12	7

病理因素	例数	Bcl-2				统计量	P值
病理因素	例数	-	+	++	+++	统计量	P值
年龄						-1.16	0.25
＜50岁	50	21	9	11	9
≥50岁	34	9	9	8	8
肿瘤直径						-0.55	0.59
＜3 cm	38	16	7	6	9
≥3 cm	46	14	11	13	8
组织学分型						-0.21	0.84
浸润性导管癌	61	23	12	13	13
浸润性小叶癌	23	7	6	6	4
组织学分级						11.47	0.00
Ⅰ级	30	5	8	6	11
Ⅱ级	30	11	6	8	5
Ⅲ级	24	14	4	5	1
临床分期						-0.54	0.59
Ⅰ+Ⅱ期	56	22	11	11	12
Ⅲ期	28	8	7	8	5
淋巴结转移						-2.02	0.04
无	31	8	6	7	10
有	53	22	12	12	7

因素	Bcl-2				r值	P值
因素	-	+	++	+++	r值	P值
ER					0.09	0.40
-	16	4	4	8
+	5	4	7	2
++	4	4	5	4
+++	5	6	3	3
PR					0.17	0.12
-	17	4	7	6
+	4	7	4	4
++	5	5	6	1
+++	4	2	2	6

Please choose a citation manager

Content to export